ViiV Healthcare   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (2009)

Organization Overview

First Clinical Trial
2009
NCT01137981
First Marketed Drug
2009
zidovudine (retrovir)
First NDA Approval
2013
dolutegravir (tivicay)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ViiV Healthcare | ViiV Healthcare Australia Pty. Ltd | ViiV Healthcare Ltd. | ViiV Healthcare (VH) | VIIV HLTHCARE